Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q417296> ?p ?o }
Showing triples 1 to 69 of
69
with 100 triples per page.
- Q417296 subject Q7071513.
- Q417296 subject Q7215865.
- Q417296 subject Q7824135.
- Q417296 subject Q8852204.
- Q417296 subject Q8965786.
- Q417296 subject Q8987379.
- Q417296 abstract "Febuxostat (INN; trade names Adenuric in Europe and New Zealand, Uloric in the US, Goturic in Latin America, Feburic in Japan) is a drug that inhibits xanthine oxidase, thus reducing production of uric acid in the body. It is used in the treatment of chronic gout and hyperuricemia.Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe. Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese "Pharmaceuticals and Medical Devices Agency" in 2011.".
- Q417296 atcPrefix "M04".
- Q417296 atcSuffix "AA03".
- Q417296 casNumber "144060-53-7".
- Q417296 drugbank "DB04854".
- Q417296 fdaUniiCode "101V0R1N2E".
- Q417296 iupacName "1,3-thiazole-5-carboxylic acid".
- Q417296 iupacName "2-(3-cyano-4-isobutoxyphenyl)-4-methyl-".
- Q417296 pubchem "134018".
- Q417296 thumbnail Febuxostat.svg?width=300.
- Q417296 wikiPageWikiLink Q105522.
- Q417296 wikiPageWikiLink Q1057079.
- Q417296 wikiPageWikiLink Q1111609.
- Q417296 wikiPageWikiLink Q111546.
- Q417296 wikiPageWikiLink Q130146.
- Q417296 wikiPageWikiLink Q133087.
- Q417296 wikiPageWikiLink Q14890102.
- Q417296 wikiPageWikiLink Q14901445.
- Q417296 wikiPageWikiLink Q14907739.
- Q417296 wikiPageWikiLink Q14916181.
- Q417296 wikiPageWikiLink Q14916190.
- Q417296 wikiPageWikiLink Q18041129.
- Q417296 wikiPageWikiLink Q18041150.
- Q417296 wikiPageWikiLink Q18939.
- Q417296 wikiPageWikiLink Q3425168.
- Q417296 wikiPageWikiLink Q407308.
- Q417296 wikiPageWikiLink Q410305.
- Q417296 wikiPageWikiLink Q412486.
- Q417296 wikiPageWikiLink Q412509.
- Q417296 wikiPageWikiLink Q418529.
- Q417296 wikiPageWikiLink Q427492.
- Q417296 wikiPageWikiLink Q49970.
- Q417296 wikiPageWikiLink Q50980.
- Q417296 wikiPageWikiLink Q528842.
- Q417296 wikiPageWikiLink Q619698.
- Q417296 wikiPageWikiLink Q692286.
- Q417296 wikiPageWikiLink Q7071513.
- Q417296 wikiPageWikiLink Q7215865.
- Q417296 wikiPageWikiLink Q7669340.
- Q417296 wikiPageWikiLink Q7824135.
- Q417296 wikiPageWikiLink Q824258.
- Q417296 wikiPageWikiLink Q8852204.
- Q417296 wikiPageWikiLink Q8965786.
- Q417296 wikiPageWikiLink Q8987379.
- Q417296 wikiPageWikiLink Q899133.
- Q417296 wikiPageWikiLink Q932661.
- Q417296 wikiPageWikiLink Q974135.
- Q417296 atcPrefix "M04".
- Q417296 atcSuffix "AA03".
- Q417296 casNumber "144060".
- Q417296 drugbank "DB04854".
- Q417296 iupacName "13".
- Q417296 iupacName "2".
- Q417296 pubchem "134018".
- Q417296 unii "101".
- Q417296 type ChemicalSubstance.
- Q417296 type Drug.
- Q417296 type ChemicalObject.
- Q417296 type Thing.
- Q417296 type Q8386.
- Q417296 comment "Febuxostat (INN; trade names Adenuric in Europe and New Zealand, Uloric in the US, Goturic in Latin America, Feburic in Japan) is a drug that inhibits xanthine oxidase, thus reducing production of uric acid in the body. It is used in the treatment of chronic gout and hyperuricemia.Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe.".
- Q417296 label "Febuxostat".
- Q417296 depiction Febuxostat.svg.